Trill Impact has closed its inaugural Ventures Fund, focusing on improved health and climate action
The closing enables continued growth for Trill Impact’s Ventures portfolio, backing innovative companies addressing the health and environmental challenges of tomorrow.
Trill Impact was founded in 2019 and has since then raised above EUR 1.3 billion in assets under management across its three strategies: Impact Private Equity, Impact Ventures and Microfinance.
The inaugural Ventures Fund has closed on above EUR 90 million with a thematic focus primarily on Life Science and Green Technology investments, with a particular emphasis on addressing underserved patient groups and backing innovative green tech solutions. The Ventures Fund has been backed by institutional investors across Europe, with Nordea and Saminvest being the largest investors.
Commenting on the closing, Partner & Head of Investor Relations at Trill Impact Advisory Johanna Levander said: “The fundraising environment for Venture Capital has been undeniably challenging lately, with a cautious sentiment and lower risk appetite across markets. We are therefore extra proud to have completed this fundraise while at the same time building a portfolio of what we see as very promising scale-ups.”
Jan Ståhlberg, Founder & Managing Partner at Trill Impact, continues:
“We are excited to see investors joining forces with Trill Impact to tackle today’s societal and environmental challenges. We believe that the Venture Capital space is particularly interesting from an investment perspective in this current macro environment.”
With the closed commitments in the Ventures Fund, Trill Impact will continue to make minority investments in mid- to late-stage companies in Europe. The investment strategy targets companies with a global product reach and aims to enable each portfolio company’s impact potential while seeking market rate returns.
Trill Impact’s Ventures portfolio today include the following companies; Cinclus Pharma, tado°, MinervaX, May Health and Open Cosmos, of which several have made progress in clinical trials and market development since Trill Impact’s investment.
Nina Rawal and Alexander Domin, Partners at Trill Impact Advisory and Co-heads of Trill Impact Ventures comment: "The closing of the fund a milestone for Trill Impact. Not only as it’s the first Ventures Fund, but to us, it also represents an opportunity to invest in transformative technologies that can contribute to the climate and health challenges the world already faces and will continue facing ahead. We are excited to support the scale up of such companies, based on the belief that they can become the market winners of tomorrow.”
Distributors for the Ventures Fund have been Nordea Asset Management, acting as business introducer globally excluding North America. For the North American market, Acalyx Advisors Inc. has acted as placement agent.
Media Contact, Trill Impact
Karin Källén, Communication Manager
karin.kallen@trillimpact.com
About Trill Impact
Trill Impact is a pioneering Impact House with around EUR 1.3 billion in assets under management across its strategies, Impact Private Equity, Impact Ventures and Microfinance, with a team of around 55 experienced professionals based in the Nordics, Germany, Luxembourg and USA. Trill Impact aims to become a force for positive change through impact private investments, delivering Real Returns and Lasting Impact for the benefit of investors, businesses and society at large - encouraging others to follow. For more information, visit: www.trillimpact.com
Tags: